The startup develops stem cell-based therapies that target leukemia, blood diseases, and tissue damage through bioengineering techniques. Their solutions enhance organ transplantation outcomes and mitigate the effects of radiation poisoning, ultimately improving patient health and longevity.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with hematologic diseases, organ transplant rejection, and musculoskeletal defects often face limited access to effective cell-based therapies. Traditional stem cell sources can be scarce, leading to delays in treatment and suboptimal outcomes. The lack of readily available, high-quality stem cells hinders advancements in regenerative medicine and limits the potential for innovative therapies.
Solution
Ossium Health addresses this challenge by establishing a novel source of stem cells derived from deceased organ donors. The company's therapeutics platform focuses on processing, banking, and deploying bone marrow-derived cell therapies at an industrial scale. By leveraging the deceased donor transplant ecosystem, Ossium Health expands the availability of life-saving stem cells for patients with critical unmet needs. Their approach ensures a consistent supply of high-quality cells, enabling timely treatment and improved outcomes in hematologic diseases, organ transplant rejection, and musculoskeletal defects. Ossium Health's platform supports both clinical and research-grade human cells, facilitating advancements from discovery to commercialization.
Target Audience
The primary target audience includes healthcare providers specializing in hematology, oncology, and transplantation, as well as life science companies and organ procurement organizations seeking to advance cell-based therapies.
Features
- Bone marrow-derived cell therapies sourced from deceased organ donors
- Proprietary processing and cryopreservation methods to maintain cell viability and function
- GMP-grade HPC, Marrow product for hematopoietic stem cell transplantation
- GMP-grade CD34+ cells selected via density gradient and immunomagnetic separation
- OssiGraft™ viable bone matrix allografts for musculoskeletal repair
- Clinical trials evaluating the safety and efficacy of allogeneic transplantation with deceased donor bone marrow
- HOPE Program expanding access to HPC, Marrow for patients ineligible for clinical trials
- AATB accreditation, ensuring adherence to the highest standards of quality and safety